Centre For Clinical Research And Biostatistics (CCRB)

Back History

1 Unique Trial Number (assigned by CCRB)

CUHK_CCT00418

2 Trial Registration Date

2014-06-10

iRegistration Status

Prospective

3 Secondary IDs

12-002

4 Source(s) of Funding

Santen Pharmaceutical Co., Ltd.

5 Primary Sponsor

Santen Pharmaceutical Co., Ltd.

6 Secondary Sponsor

N/A

Function

Not Applicable

Please specify

7Responsible Contact Person (public contact person for patients interested in participating)

i Name

Miss Wong Sin Ting Janice

ii Address

3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Mongkok, Kowloon, Hong Kong

iii Phone

39435825

iv Email

janicewong@cuhk.edu.hk

v Affiliation

The Chinese University of Hong Kong

vi Country

Hong Kong

8Research Contact Person (person to contact for scientific inquiries)

i Name

Prof. Tham Chee-yung, Clement

ii Address

3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Mongkok, Kowloon, Hong Kong

iii Phone

3943 5823

iv Email

clemtham@cuhk.edu.hk

v Affiliation

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

vi Country

Hong Kong

9 Official Scientific Title of the Study

A Study on the 24-hour Intraocular Pressure Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma or Ocular Hypertension

10 Public Title

A Study on the 24-hour Intraocular Pressure Profile of the 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma or Ocular Hypertension

i Public Title in Chinese 研究名稱

對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost（他氟前列素）滴眼液後的24小時眼球內壓概況的研究

11 Short Title (Optional)

24hr study

12 Countries of Recruitment

Hong Kong

13Research Ethic Review

i Has the study received appropriate ethics approval?

Yes

ii When is the approval date?

2012-10-19

iii Full Name of IRB/IEC

Kowloon Central Cluster REC / Kowloon East Cluster REC

Please specify

iv IRB/IEC approval reference number

KC/KE 12-0100/FR-2

14 Medical Condition Being Studied

Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Ocular Hypertension

15Intervention

i Types of intervention

Drug

Please specify

ii Description/ name of Intervention/article

0.0015% tafluprost ophthalmic solution with 0.001% BAK

iii Dosage form of the intervention

Eyedrop

iv Dosage of the intervention

0.0015% aqueous ophthalmic solution

v Duration of the intervention

Two Months

vi Frequency of the intervention

Once Daily

16Comparative Treatments

i Description/ name of comparative treatments

Colorless clear 0.0015% aqueous ophthalmic solution containing 15 µg of tafluprost in 1 ml
One drop is instilled to the affected eye(s), once daily (same as the approved dosage).

ii Dosage form of the comparative treatments

Eyedrop

iii Dosage of the comparative treatments

0.0015% aqueous ophthalmic solution

iv Duration of the comparative treatments

Two Months

v Frequency of the comparative treatments

Once Daily

17Key Inclusion and Exclusion Criteria

i Inclusion Criteria

1) Primary open angle glaucoma, primary angle closure glaucoma or ocular hypertension.
2) Above those who are currently on anti-glaucoma medication (beta-blocker, carbonic anhydrase inhibitor or their combination) and insufficiently controlled.
3) Baseline IOP is 21mmHg or higher (for PACG patient, IOP is to be 21mmHg or higher after laser iridotomy or laser iridoplasty is conducted).
4) Those who can visit the clinic on the designated day as instructed by the physician

ii Exclusion Criteria

1) History of intra-ocular surgery (not including laser iridotomy or laser iridoplasty conducted for PACG patients)
2) In case of primary angle closure, laser iridotomy or laser iridoplasty within one month prior to giving the informed consent is conducted.
3) Patients who are treated by prostaglandin analogues or its combinations.
4) History of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product
5) Presence of any corneal disorder that may interfere with accurate IOP measurement using applanation tonometry.
6) Presence of corneal disorder that may interfere with accurate 24 hour IOP measurement using contact lens device.
7) Patients who are treated by steroids.(e.g. dexamethasone, hydrocortisone sodium succinate, prednisolone acetate)
8) Female patients who are pregnant, nursing or planning a pregnancy
9) Patients wearing glasses with metal frames
10) Patients with severe dry eye syndrome

iii Age Minimum

18 years of age or above

iv Age Maximum

999

v Gender

Both Male and Female

18 Study Type

Interventional

19Study Design

i Randomization

Non-randomized

Please specify

ii Nature of control

Uncontrolled

iii Degree of masking

Open label

If Single-blind, who will be masked?

iv Group Assignment

Single group

v Study Phase

4

Please specify

vi Study Objectives (Optional)

20 Anticipated trial start date

2014-06-24

21 Target Sample Size

15

22 Recruitment Status

Complete

23 Primary Outcome

24-hour IOP variation

24 Secondary Outcome

IOP-lowering effect

25Study Information/Publication

i Study Information/Publication Available?

No

ii Link to Study Information/Publication

26Last Update Date

2018-04-20

27 Primary Registry and Trial Identifying Number

ChiCTR-ONC-14004780

28 Date of Registration in Primary Registry

2014-06-10

Back History

Trial Detail